Extended Data Fig. 6: T cell responses following vaccination with BNT162b2.

Correlation between T cell responses against SARS-CoV-2 spike peptide pool and serum neutralization of spike (D614G) pseudotyped lentiviral particles (ID50). a, b, Correlation of IFNγ (a, n = 79) and IL-2 (b, n = 69) FluoroSpot and ID50 after first dose. Linear regression lines with 95% CI are plotted. Bonferroni adjustment was made for multiple comparisons. c, FluoroSpot IFNγ PBMC responses to peptide pool of CEF peptide pool. Responses from unexposed PBMCs (stored from 2014–2016, n = 20), <80 years group (n = 46) and ≥80 years group (n = 35) three weeks after the first dose of vaccine. d, e, FluoroSpot analysis for IFNγ (d) and IL-2 T cell responses (e) specific to SARS-CoV-2 spike protein peptide pool following stimulation of PBMCs from infected donors (n = 46), unexposed donors (n = 20) and vaccinated individuals three weeks or more after the first dose (IFNγ, n = 77; IL-2, n = 64) and three weeks after the second dose (IFNγ and IL-2, n = 39). f–i, Human cytomegalovirus serostatus, T cell responses and serum neutralization of spike (D614G) pseudotyped lentiviral particles (ID50) after the first dose of vaccine. f, HCMV serostatus for <80- and ≥80-year age groups (n = 72). g, h, IFNγ (g, n = 72) and IL-2 (h, n = 64) FluoroSpot responses after the first dose. i, ID50 after the first dose by CMV serostatus. Error bars, s.d.